[Drug treatments for uterine fibroma: rationale].
Fernandez
H
H
Azoulay
C
C
Rostoker
G
G
D000328:Adult; D003276:Contraceptives, Oral / Q000627:therapeutic use; D003582:Cytogenetics; D005260:Female; D030342:Genetic Diseases, Inborn; D012739:Gonadal Steroid Hormones / Q000502:physiology; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D008875:Middle Aged; D011300:Preoperative Care; D011374:Progesterone / Q000502:physiology; D011372:Progestins / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology
D003276:Contraceptives, Oral; D012739:Gonadal Steroid Hormones; D006133:Growth Substances; D011372:Progestins; D020845:Selective Estrogen Receptor Modulators; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone